Skip to main content
Log in

Expansion of CD3+CD56+ lymphocytes correlates with induction of cytotoxicity by interleukin-2 gene transfer in human breast tumor cultures

  • Original Articles
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background: Mice immunized with murine mammary carcinoma cells genetically engineered to secrete interleukin-2 (IL-2) are rendered resistant to subsequent challenge with unmodified tumor cells, and in the case of mice bearing established tumors, the rate of development of pulmonary metastases is reduced. Despite these encouraging animal results, little is known about the induction of antitumor immunity by IL-2 gene transfer in human breast cancer.

Methods: Adenovirally mediated IL-2 gene transfer was performed in 12 tumor fragment cultures established from seven primary breast cancers. Autologous tumor infiltrating lymphocytes (TILs) or peripheral blood mononuclear cells (PBMCs) were cocultured with transduced tumor fragments, and changes in phenotype and cytotoxicity were measured.

Results: IL-2 was never detectable in the untransduced cultures, but it peaked at 5.0—1,324.8 ng/ml in the transduced cultures. Lymphocyte counts declined in all untransduced cultures, but they increased two- to sevenfold in four transduced cultures. CD4:CD8 ratios decreased from a mean of 2.11 at baseline to 1.27 after stimulation in coculture (p=0.03). Expansion of lymphocytes expressing the natural killer cell phenotype (CD3CD56+) occurred in only one culture, but the CD3+CD56+ population increased in four of six cultures. Lymphocytes from four of 10 cocultures generated significant cytotoxicity against allogeneic breast cancer cells. Induction of cytotoxicity correlated with expansion of the CD3+CD56+ phenotype (R2=0.805, p=0.02).

Conclusions: IL-2 gene expression by human breast cancer causes expansion of CD3+CD56+ cytotoxic lymphocytes. This phenotype is consistent with that of a non-major histocompatibility complex (MHC)-restricted cytokine induced killer cell population previously described.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Runnebaum IB, Kreienberg R. p53 trans-dominantly suppresses tumor formation of human breast cancer cells mediated by retroviral bulk infection without marker gene selection: an expeditious in vitro protocol with implications towards gene therapy.Hybridoma 1995;14:153–7.

    CAS  PubMed  Google Scholar 

  2. Neuenschwander S, Roberts CT Jr, LeRoith D. Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor I receptor antisense ribonucleic acid.Endocrinology 1995;136:4298–303.

    Article  CAS  PubMed  Google Scholar 

  3. Miller A, McBride W, Dubinett S, et al. Transduction of human melanoma cell lines with the human interleukin-7 gene using retroviral-mediated gene transfer: comparison of immunological properties with IL-2.Blood 1993;82:3686–94.

    CAS  PubMed  Google Scholar 

  4. Gansbacher B, Zier K, Daniels B, et al. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity.J Exp Med 1990;172:1217–24.

    Article  CAS  PubMed  Google Scholar 

  5. Tsai S, Gansbacher B, Tait L, et al. Induction of anti-tumor immunity by interleukin-2 gene-transduced mouse mammary tumor cells versus transduced mammary stromal fibroblasts. J Natl Cancer Inst 1993;85:546–53.

    CAS  PubMed  Google Scholar 

  6. Fearon E, Pardoll D, Itaya T, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of antitumor responses.Cell 1990;60:397–403.

    Article  CAS  PubMed  Google Scholar 

  7. Allione A, Consalvo M, Nanni P, et al. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants.Cancer Res 1994;54:6022–6.

    CAS  PubMed  Google Scholar 

  8. Matory Y, Chen M, Goedegebuure P, Eberlein T. Anti-tumor activity of three mouse mammary cancer cell lines following cytokine gene transfection. 47th Annual Cancer Symposium of the Society of Surgical Oncology, March 17–20, 1994, Houston, TX.

  9. Eamonn C, Clary B, DiMaio J, et al. Inhibition of breast cancer metastasis by cytokine gene-modified tumor vaccination in tumorbearing mice.JAMA 1994;272:1485.

    Google Scholar 

  10. Karp SE, Farber A, Salo JC, et al. Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma. Tumor inhibition by IL-2 but not tumor necrosis factor.J Immunol 1993;150:896–908.

    CAS  PubMed  Google Scholar 

  11. Miller AR, McBride WH, Hunt K, Economou JS. Cytokinemediated gene therapy for cancer.Ann Surg Oncol 1994;1:436–50.

    Article  CAS  PubMed  Google Scholar 

  12. Musiani P, Modesti A, Brunetti M, et al. Nature and potential of the reactive response to mouse mammary adenocarcinoma cells engineered with interleukin-2, interleukin-4 or interferon-gamma genes.Nat Immun 1994;13:93–101.

    CAS  PubMed  Google Scholar 

  13. Rosen P. The pathobiology of breast carcinoma. In: Harris J, Hellman S, Henderson I, eds.Breast Diseases. Philadelphia: JB Lippincott, 1987;147–209.

    Google Scholar 

  14. Baxevanis CN, Dediussis GVC, Papadoupoulos NG, et al. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.Cancer 1994;74:1275–82.

    CAS  PubMed  Google Scholar 

  15. McGregory WJ, Bautista DS, Graham FL. A simple technique for the rescue of early region I mutations into infectious adenovirus type 5.Virology 1988;163:614–7.

    Google Scholar 

  16. Graham FL, Prevac L. Gene transfer and expression protocols. In: Murray EJ, ed.Methods in Molecular Biology, Vol. 7. Clifton, NJ: Humana Press, 1991.

    Google Scholar 

  17. Wright SC, Wilbur SM. Biochemical characterization of natural killer cytotoxic factors.Adv Exp Med 1985;184:179–81.

    CAS  Google Scholar 

  18. Band V, Sager R. Distinctive traits of normal and tumor-derived human mammary epithelial cells expressed in a medium that supports long-term growth of both cell types.Proc Natl Acad Sci USA 1989;86:1249–53.

    CAS  PubMed  Google Scholar 

  19. Miescher S, Whiteside TL, Carrel S, et al. Functional properties of tumor infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes.J Immunol 1986;136:1899.

    CAS  PubMed  Google Scholar 

  20. Uchiyama A, Hoon DSB, Morisaki T, et al. Transfection of interleukin 2 gene into human melanoma cells augments cellular immune response.Cancer Res 1993;53:949–52.

    CAS  PubMed  Google Scholar 

  21. Sairenji M, Yanoma S, Motohashi H, et al. Induction of cytolytic activity of lymphocytes from carcinomatous pleural effusion by IL-2 and autologous tumor cells.Biotherapy 1994;6:283–90.

    Google Scholar 

  22. Euhus D. High efficiency adenoviral-mediated gene transfer into human breast cells. 48th Annual Cancer Symposium of the Society of Surgical Oncology, March 23–26, 1995, Boston, MA.

  23. Yannelli JR, Hyatt C, Johnson S, et al. Characterization of human tumor cell lines transduced with the cDNA encoding either necrosis factor alpha (TNF-α) or interleukin-2 (IL-2).J Immunol Methods 1993; 161:77–90.

    Article  CAS  PubMed  Google Scholar 

  24. Ortaldo JR, Mason A, Overton R. Lymphokine activated killer cells. Analysis of progenitors and effectors.J Exp Med 1986;164:1193–205.

    Article  CAS  PubMed  Google Scholar 

  25. Phillips JH, Lanier LL. Dissection of the lymphokine-activated killer phenomenon: relative contribution of peripheral blood natural killer cells and T-lymphocytes to cytolysis.J Exp Med 1986;164:814–25.

    Article  CAS  PubMed  Google Scholar 

  26. Euhus D, Kimura L. Characterization of lymphocytes infiltrating breast cancers and surrounding normal breast tissue.Breast Cancer Res Treat 1995;37(suppl):109.

    Google Scholar 

  27. Schmidt-Wolf IGH, Lefterova P, Mehta BA, et al. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells.Exp Hematol 1993;21:1673–9.

    CAS  PubMed  Google Scholar 

  28. Yasumura S, Higuchi K, Hioki O, et al. Induction of allogeneic tumor- and lymphokine-activated lymphocytes against hepatocellular carcinoma.J Gastroenterol Hepatol 1992;7:136–41.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Euhus, D.M., Kimura, L. & Arnold, B. Expansion of CD3+CD56+ lymphocytes correlates with induction of cytotoxicity by interleukin-2 gene transfer in human breast tumor cultures. Annals of Surgical Oncology 4, 432–439 (1997). https://doi.org/10.1007/BF02305558

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02305558

Key Words

Navigation